Dumitru Irina Magdalena, Dumitru E., Rugina S., Dumitru A.
Abstract: The evaluation of albendazol treatment's efficacy in hydatid cysts (CH) with different locations and the evaluation of treatment’s efficacy based on: cysts' location, size, type and immunological status of patient. We performed a prospective study on 320 patients, during 5 years. We performed the drugbased treatment in cases of small and medium cysts sizes (< 7 cm). Statistics do not show a significant difference between the hepatic and pulmonary hydatic cysts’ healing rates, p > 0.05 (p = 0.5987). Albendazol treatment’s efficacy is higher in the case of hepatic localization than in other localizations. The efficacy of the albendazol therapy is significantly higher in the case of CH < 7cm in comparison with CH > 7cm, which requests a surgical treatment. The efficacy of the albendazol treatment is higher in the case of type 1 hydatic cysts than in the case of type 2 hydatic cysts. Patients with CD4 > 944 cells/mm3 responded better to treatment in comparison with the patients with CD4 < 944 cells/mm3. The efficiency of the albendazol treatment is lower for the patients presenting co-morbidities. Treating hidatid diseases with albendazol 800mg/day for 4 weeks, in repeated cures separated by free intervals of 2 weeks, had as a result the healing of 91.25% of the cases. The positive predictive factors of the albendazol treatment response were: hepatic or pulmonary localization of the hydatid cysts, small dimensions, below 7cm in diameter, presence of the type1 hydatid cists, absence of co-morbidities and unaltered immunological status (CD4 > 944 cells/mm3).